Genomic Health, Inc. (GHDX) COO Sells $3,693,585.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) COO Frederic Pla sold 43,500 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $84.91, for a total value of $3,693,585.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Frederic Pla also recently made the following trade(s):

  • On Monday, October 8th, Frederic Pla sold 1,500 shares of Genomic Health stock. The shares were sold at an average price of $65.43, for a total value of $98,145.00.

Genomic Health stock opened at $81.67 on Friday. The firm has a market capitalization of $3.23 billion, a P/E ratio of 8,167.00 and a beta of 0.44. Genomic Health, Inc. has a 52 week low of $26.54 and a 52 week high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.28. The company had revenue of $101.30 million during the quarter, compared to analyst estimates of $94.27 million. Genomic Health had a return on equity of 14.76% and a net margin of 4.95%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.06) earnings per share. Equities analysts predict that Genomic Health, Inc. will post 1.06 EPS for the current fiscal year.

GHDX has been the subject of several analyst reports. Zacks Investment Research lowered Genomic Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 24th. Piper Jaffray Companies upped their target price on Genomic Health from $34.00 to $50.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. Jefferies Financial Group reiterated a “hold” rating and issued a $50.00 target price on shares of Genomic Health in a research note on Friday, August 3rd. Canaccord Genuity upped their target price on Genomic Health from $56.00 to $62.00 and gave the company a “buy” rating in a research note on Friday, August 3rd. Finally, Cowen reiterated a “hold” rating and issued a $50.00 target price on shares of Genomic Health in a research note on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $48.33.

Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its stake in Genomic Health by 30.7% during the second quarter. Bank of New York Mellon Corp now owns 122,246 shares of the medical research company’s stock worth $6,161,000 after acquiring an additional 28,710 shares during the last quarter. Millennium Management LLC increased its stake in Genomic Health by 114.0% during the second quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock worth $72,891,000 after acquiring an additional 770,413 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in Genomic Health during the second quarter worth about $213,000. State of Wisconsin Investment Board increased its stake in Genomic Health by 40.7% during the second quarter. State of Wisconsin Investment Board now owns 21,100 shares of the medical research company’s stock worth $1,063,000 after acquiring an additional 6,100 shares during the last quarter. Finally, Sei Investments Co. increased its stake in Genomic Health by 3,653.2% during the second quarter. Sei Investments Co. now owns 25,447 shares of the medical research company’s stock worth $1,282,000 after acquiring an additional 24,769 shares during the last quarter. Institutional investors own 89.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.wkrb13.com/2018/11/11/genomic-health-inc-ghdx-coo-sells-3693585-00-in-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

See Also: How Do I Invest in Dividend Stocks

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply